POMPANO BEACH, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. BSEM (“BioStem”, “we”, “us”, or “our”), a number one MedTech firm centered on the event, manufacturing, and commercialization of placental-derived merchandise for superior wound care, as we speak introduced chosen preliminary monetary outcomes for the fiscal fourth quarter and full yr ended December 31, 2024.
2024 Preliminary Fourth Quarter and 12 months Finish Outcomes:
- Fourth quarter internet income is predicted to be roughly $102.9 million, which represents a 794% enhance over the fourth quarter of 2023, pushed by strong efficiency throughout the product portfolio.
- Full-year 2024 internet income is predicted to be roughly $301.8 million, up from $16.7 million for fiscal yr 2023, reflecting a rise of $285.1 million, or 1,702%.
- Fourth quarter gross revenue is predicted to be roughly $99.3 million, in comparison with $10.9 million for the fourth quarter of 2023, which represents an 811% enhance.
- Full-year 2024 gross revenue is predicted to be roughly $288.1 million, in comparison with $15.4 million for fiscal yr 2023, which represents an 1,775% enhance.
- This distinctive year-over-year progress displays the strong adoption of AmnioWrap2 OneView™ within the post-acute care market and the profitable introduction of Vendaje AC®, supported by the focused business methods of Enterprise Medical, LLC (“Enterprise”), BioStem’s unique gross sales and advertising and marketing associate. Leveraging the superior analytics and market insights offered by the Enterprise OneView™ platform, BioStem has successfully expanded its market presence, driving accelerated product adoption and strengthening its place as a frontrunner in superior wound care options.
“2024 has been a unprecedented and transformative yr for BioStem, outlined by record-breaking progress and a collection of groundbreaking milestones that underscore our management in superior wound care,” stated Jason Matuszewski, Chief Govt Officer of BioStem. “Attaining over 1,700% year-over-year income progress is a testomony to the relentless execution of our strategic initiatives, the innovation behind our merchandise like AmnioWrap2™ and the newly-launched Vendaje AC®, and the dedication of our workforce.
Our success has been additional catalyzed by our valued partnership with Enterprise and their state-of-the-art Enterprise OneView™ platform, which has revolutionized our distribution capabilities, enhanced visibility throughout the market, and accelerated product adoption. This synergy exemplifies the facility of collaboration in driving impactful outcomes.
As we glance to 2025, I’m energized by the alternatives forward, notably the anticipated finalization of the LOI with ProgenaCare, a key step in broadening our product portfolio and deepening our impression throughout the continuum of wound care. Coupled with our investments in R&D, medical trials, and the growth of our world-class workforce, we imagine this acquisition positions us to proceed delivering cutting-edge options that enhance affected person outcomes and create lasting worth for all stakeholders.
We’re deeply grateful for the unwavering help of our shareholders, clients, and companions, and we stay dedicated to leveraging innovation, collaboration, and excellence to form the way forward for wound care and past.”
About BioREtain®:
BioStem’s placental allografts are processed using BioStem’s proprietary BioREtain®technique, which preserves the tissue’s endogenous organic properties whereas sustaining the construction and matrix present in contemporary perinatal tissue. The patented six-step BioREtain®course of is mild, minimally invasive, and preserves the pure integrity of the amniotic tissue/elements important to the wound therapy course of. For a full overview of BioREtain, please go to: https://biostemtechnologies.com/our-science/#six-steps.
Be a part of BioStem’s Distribution Checklist & Social Media:
To comply with the most recent developments at BioStem, sign-up to BioStem’s e mail distribution checklist HERE, and comply with us on Twitter and LinkedIn.
About BioStem Applied sciences, Inc. BSEM:
BioStem Applied sciences is a number one innovator centered on harnessing the pure properties of perinatal tissue within the growth, manufacture, and commercialization of allografts. BioStem is targeted on manufacturing merchandise that change lives, leveraging its proprietary BioREtain® processing technique. BioREtain® has been developed by making use of the most recent analysis in superior wound care, centered on sustaining progress elements and preserving tissue construction. BioStem Applied sciences’ high quality administration system and commonplace working procedures have been reviewed and accredited by the American Affiliation of Tissue Banks (“AATB”). These programs and procedures are established per present Good Tissue Practices (“cGTP”) and present Good Manufacturing Processes (“cGMP”). Our portfolio of high quality manufacturers consists of AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Every BioStem Applied sciences placental allograft is processed at BioStem’s FDA registered and AATB accredited website in Pompano Seashore, Florida. For extra data go to biostemtechnologies.com and comply with us on Twitter and LinkedIn.
Ahead-Wanting Statements:
Aside from statements of historic reality, this launch additionally incorporates forward-looking statements throughout the that means of relevant securities legal guidelines. These forward-looking statements relate to expectations or forecasts of future occasions. Ahead-looking statements could also be recognized utilizing phrases similar to “forecast,” “intend,” “search,” “goal,” “anticipate,” “imagine,” “anticipate,” “estimate,” “plan,” “outlook,” and “undertaking” and different related expressions that predict or point out future occasions or traits or that aren’t statements of historic issues. Ahead-looking statements on this launch embody statements concerning BioStem’s plans and expectations for future efficiency, together with: (i) BioStem’s expectations about projected internet income and gross revenue for the quarter and yr finish; (ii) BioStem’s expectations concerning product adoption and market presence; (iii) BioStem’s strategic initiatives in addition to its skill to speed up progress in 2025 and past; (iv) BioStem’s expectations concerning its timing and talent to shut the Progenacare acquisition pursuant to the phrases of any settlement entered into by and between the events, in addition to any impression that such acquisition could have on BioStem’s enterprise and operations and (v) BioStem’s ongoing dedication to leverage innovation and collaboration to ship cutting-edge options that enhance affected person outcomes and create lasting worth for stakeholders. The precise monetary and working outcomes that will likely be mirrored in its audited monetary statements, when they’re accomplished and publicly disclosed, could differ from these preliminary outcomes.
Ahead-looking statements with respect to the operations of BioStem, methods, prospects and different facets of the enterprise of BioStem are based mostly on present expectations which might be topic to recognized and unknown dangers and uncertainties, which might trigger precise outcomes or outcomes to vary materially from expectations expressed or implied by such forward-looking statements. The next is a listing of things, amongst others, that would trigger precise outcomes to vary materially from these contemplated by the forward-looking statements: the impression of any modifications to the reimbursement ranges for BioStem’s merchandise; the numerous and persevering with competitors that BioStem faces, which might adversely have an effect on its enterprise, outcomes of operations and monetary situation; fast technological change that would trigger BioStem’s merchandise to turn out to be out of date, and the chance that if BioStem doesn’t improve its product choices via its analysis and growth efforts, it might be unable to successfully compete; BioStem’s skill to persuade physicians that its merchandise are secure and efficient alternate options to current therapies and that its merchandise needs to be used of their procedures; BioStem’s skill to lift funds to increase its enterprise; the chance that BioStem could incur vital losses sooner or later; modifications in relevant legal guidelines or laws; the likelihood that BioStem could also be adversely affected by different financial, enterprise, and/or aggressive elements; BioStem’s skill to keep up manufacturing of its merchandise in adequate portions to fulfill demand; and the Firm’s skill to consummate an settlement with Progenacare. You need to rigorously contemplate the foregoing elements and the opposite dangers and uncertainties described within the “Danger Elements” part of the Registration Assertion on Kind 10, and any subsequent amendments, initially filed with the Securities and Trade Fee (“SEC”) on September 27, 2024, and in any subsequent filings with the SEC.
You’re cautioned to not place undue reliance upon any forward-looking statements, which communicate solely as of the date made. Though it might voluntarily accomplish that once in a while, BioStem undertakes no dedication to replace or revise the forward-looking statements, whether or not because of new data, future occasions or in any other case, besides as required by relevant securities legal guidelines.
BioStem Applied sciences, Inc.
Cellphone: 954-380-8342
Web site: http://www.biostemtechnologies.com
E-Mail: [email protected]
Twitter: @BSEM_Tech
Fb: BioStemTechnologies
PCG Advisory
Jeff Ramson
[email protected]
646-863-6893
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
